Merck, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: -

Market Cap: $295.3B

Website: http://www.merck.ph

Clinical Trials

Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003, KEYVIBE-003)

Phase 3

Active, not recruiting

Conditions: Lung Neoplasms
Non-Small-Cell Lung Carcinoma

Interventions: Biological: Pembrolizumab/Vibostolimab
Biological: Pembrolizumab

First Posted Date: 2021-02-04

Last Posted Date: 2025-03-30

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 1264

Registration Number: NCT04738487

Locations: 🇺🇸
Boca Raton Regional Hospital ( Site 0004), Boca Raton, Florida, United States
🇺🇸
Illinois Cancer Care ( Site 0026), Peoria, Illinois, United States
🇺🇸
Mercy Research - David C. Pratt Cancer Center ( Site 0025), Saint Louis, Missouri, United States

and more 185 locations

A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)

Phase 3

Active, not recruiting

Conditions: Carcinoma, Renal Cell

Interventions: Biological: Pembrolizumab
Biological: Pembrolizumab/Quavonlimab
Drug: Belzutifan
Drug: Lenvatinib

First Posted Date: 2021-02-03

Last Posted Date: 2024-11-18

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 1653

Registration Number: NCT04736706

Locations: 🇺🇸
Hartford Hospital ( Site 0024), Hartford, Connecticut, United States
🇺🇸
Cedars Sinai Medical Center ( Site 0027), Los Angeles, California, United States
🇺🇸
New England Cancer Specialists ( Site 0082), Scarborough, Maine, United States

and more 259 locations

A Study of the Efficacy and Safety of Frespaciguat (MK-5475) in Participants With Pulmonary Arterial Hypertension (INSIGNIA-PAH: Phase 2/3 Study of an Inhaled sGC Stimulator in PAH) (MK-5475-007)

Phase 2

Completed

Conditions: Pulmonary Arterial Hypertension
Hypertension, Pulmonary

Interventions: Drug: Frespaciguat
Drug: Placebo to Frespaciguat

First Posted Date: 2021-02-01

Last Posted Date: 2025-05-25

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 168

Registration Number: NCT04732221

Locations: 🇨🇦
University Health Network - Toronto General Hospital ( Site 0104), Toronto, Ontario, Canada
🇦🇷
Hospital Universitario Austral ( Site 0138), Pilar, Buenos Aires, Argentina
🇩🇪
Thoraxklinik Heidelberg gGmbH am Universitaetsklinikum Heidelberg ( Site 0276), Heidelberg, Baden-Wurttemberg, Germany

and more 88 locations

Cognition Platform Study in Participants at Risk for Alzheimer's Disease (AD) (MK-0000-413)

Phase 1

Completed

Conditions: Alzheimer's Disease
Mild Cognitive Impairment

Interventions: Drug: Placebo
Drug: Donepezil

First Posted Date: 2021-01-29

Last Posted Date: 2024-10-28

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 44

Registration Number: NCT04730635

Locations: 🇺🇸
Velocity Clinical Research, Hallandale Beach ( Site 0013), Hallandale Beach, Florida, United States
🇦🇺
Royal Adelaide Hospital-CALHN Memory Trials ( Site 0031), Adelaide, South Australia, Australia
🇺🇸
Insight Clinical Trials ( Site 0020), Beachwood, Ohio, United States

and more 7 locations

Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)

Phase 2

Recruiting

Conditions: Non-Hodgkins Lymphoma
Hematologic Malignancies
Waldenstroms Macroglobulinaemia
Chronic Lymphocytic Leukaemia

Interventions: Drug: Nemtabrutinib

First Posted Date: 2021-01-28

Last Posted Date: 2025-05-31

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 490

Registration Number: NCT04728893

Locations: 🇺🇸
Highlands Oncology Group ( Site 2728), Springdale, Arkansas, United States
🇺🇸
University of California San Diego Moores Cancer Center ( Site 2717), La Jolla, California, United States
🇺🇸
Lundquist Institute for Biomedical Innovation at Harbor-UCLA-Hematology and Medical Oncology ( Site 2724), Torrance, California, United States

and more 118 locations

Pembrolizumab/Vibostolimab Coformulation (MK-7684A) or Pembrolizumab/Vibostolimab Coformulation Plus Docetaxel Versus Docetaxel for Metastatic Non Small Cell Lung Cancer (NSCLC) With Progressive Disease After Platinum Doublet Chemotherapy and Immunotherapy (MK-7684A-002, KEYVIBE-002)

Phase 2

Completed

Conditions: Metastatic Non Small Cell Lung Cancer

Interventions: Biological: Pembrolizumab/Vibostolimab coformuation
Drug: Docetaxel
Drug: Placebo

First Posted Date: 2021-01-26

Last Posted Date: 2024-11-13

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 255

Registration Number: NCT04725188

Locations: 🇺🇸
Cedars-Sinai Medical Center ( Site 2522), Los Angeles, California, United States
🇺🇸
University of Maryland ( Site 2528), Baltimore, Maryland, United States
🇧🇪
UZ Brussel ( Site 0336), Brussels, Bruxelles-Capitale, Region De, Belgium

and more 92 locations

Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)-China Extension Study

Phase 3

Completed

Conditions: Nonsquamous Non-small Cell Lung Cancer

Interventions: Biological: Pembrolizumab
Drug: Carboplatin
Drug: Cisplatin
Drug: Pemetrexed
Drug: Placebo matching lenvatinib
Drug: Lenvatinib

First Posted Date: 2021-01-20

Last Posted Date: 2024-10-04

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 201

Registration Number: NCT04716933

Locations: 🇨🇳
Fujian Provincial Cancer Hospital ( Site 0102), Fuzhou, Fujian, China
🇨🇳
Cancer Hospital Affiliated to Xinjiang Medical University ( Site 0110), Urumuqi, Xinjiang, China
🇨🇳
The First Affiliated Hospital of Wenzhou Medical University ( Site 0124), Wen Zhou, Zhejiang, China

and more 16 locations

Safety and Immunogenicity of Extended 2-dose Regimens of 9-valent Human Papillomavirus (9vHPV) Vaccine (V503-069)

Phase 3

Active, not recruiting

Conditions: Papillomavirus Infections

Interventions: Biological: 9vHPV vaccine

First Posted Date: 2021-01-13

Last Posted Date: 2025-04-20

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 700

Registration Number: NCT04708041

Locations: 🇲🇽
CAIMED México ( Site 0207), Mexico City, Distrito Federal, Mexico
🇵🇱
Gravita Diagnostyka i Leczenie Nieplodnosci ( Site 0555), Lodz, Lodzkie, Poland
🇵🇱
ALERGO-MED Specjalistyczna Przychodnia Lekarska ( Site 0557), Tarnow, Malopolskie, Poland

and more 27 locations

Pembrolizumab Plus Lenvatinib for First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (1L nccRCC) (MK-3475-B61)

Phase 2

Active, not recruiting

Conditions: Renal Cell Carcinoma

Interventions: Biological: Pembrolizumab
Drug: Lenvatinib

First Posted Date: 2021-01-11

Last Posted Date: 2025-02-17

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 160

Registration Number: NCT04704219

Locations: 🇺🇸
Comprehensive Cancer Centers of Nevada ( Site 0010), Las Vegas, Nevada, United States
🇺🇦
Chernihiv Medical Center of Modern Oncology ( Site 0509), Chernihiv, Chernihivska Oblast, Ukraine
🇷🇺
Russian Scientific Center of Radiology-Russian Scientific Center of Radiology ( Site 0602), Moscow, Moskva, Russian Federation

and more 53 locations

Substudy 02D: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Melanoma Brain Metastasis (MK-3475-02D/KEYMAKER-U02)

Phase 1

Active, not recruiting

Conditions: Melanoma

Interventions: Biological: Pembrolizumab
Biological: Pembrolizumab/Quavonlimab
Drug: Lenvatinib

First Posted Date: 2021-01-07

Last Posted Date: 2025-04-03

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 300

Registration Number: NCT04700072

Locations: 🇺🇸
The Angeles Clinic and Research Institute ( Site 4009), Los Angeles, California, United States
🇺🇸
UCLA Hematology & Oncology ( Site 4004), Los Angeles, California, United States
🇺🇸
Martha Morehouse Tower ( Site 4020), Columbus, Ohio, United States

and more 33 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy